Skip To Main Content
Mefküre Durmuş on Muck Rack

Mefküre Durmuş

As seen in: European Journal of Hospital Pharmacy
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Mefküre

Contact Mefküre, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Can antibiotics affect the clinical features of patients with candidemia? The retrospective evaluation of 5 years of data in an intensive care unit

|
By Mefküre Durmuş, Serkan Kalkan, Sena Güzel Karahan, Murat Biçakcioğlu
| European Journal of Hospital Pharmacy Verified
Abstract Background Candidemia is an opportunistic infection of intensive care units (ICUs) and causes morbidity and mortality. Multiple antibiotic exposure was found to be an independent risk factor for mortality and non-albicans candidemia (NAC) in candidemia patients.
Open in Who Shared Issue with article?

Can antibiotics affect the clinical features of patients with candidemia? The retrospective evaluation of 5 years of data in an intensive care unit

|
By Mefküre Durmuş, Serkan Kalkan, Sena Güzel Karahan, Murat Biçakcioğlu
| European Journal of Hospital Pharmacy Verified
Mefküre Durmuş1, Serkan Kalkan2, http://orcid.org/0000-0003-0818-2665Sena Güzel Karahan1, Murat Biçakcioğlu2, Nesligül Özdemir3, Zeynep Ülkü Gün1, Ayşe Belin Özer2 1Clinical Pharmacy, İnönü University Faculty of Pharmacy, Malatya, Turkey 2Anesthesiology and Reanimation, İnönü University Faculty of Medicine, Malatya, Turkey 3Clinical Pharmacy, Hacettepe University, Ankara, Turkey Correspondence to Mrs Sena Güzel Karahan, Department of Clinical Pharmacy, Inonu University, Malatya 44210, Turkey;...
Open in Who Shared Issue with article?

The safety profile of favipiravir in COVID‐19 patients with severe renal impairment

|
By Selim Gök, Ömer Faruk Bahçecioğlu, Mefküre Durmuş, Zeynep Ülkü Gün
| Wiley Online Library Verified
What’s known In COVID-19 patients, chronic renal disease is linked to an increase in morbidity and mortality. Despite the lack of safety data for favipiravir in patients with renal failure, the emergence of COVID-19 justifies its usage in this population. Favipiravir-related side effects (eg, hepatocellular injury) are well known, although the risk factors that lead to these side effects are unknown.
Open in Who Shared Issue with article?
See all 8 articles